ORLANDO, Fla., May 29, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced interim data from a Phase 2 randomized clinical trial of oral sapacitabine (CYC682), a novel nucleoside analog, in elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) (Abstract 7021). The data demonstrated that oral sapacitabine is active in AML across all three dosing schedules tested and that prolonged administration is feasible in the outpatient setting. Activity was also observed in the ongoing MDS stratum of the study. Based on the data, Cyclacel intends to use the 3-day dosing schedule for further clinical development in elderly AML and will discuss with the FDA the design of a pivotal study in elderly patients with AML expected to commence in 2009.
